These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29049492)

  • 1. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
    Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
    JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
    Hearn JWD; AbuAli G; Reichard CA; Reddy CA; Magi-Galluzzi C; Chang KH; Carlson R; Rangel L; Reagan K; Davis BJ; Karnes RJ; Kohli M; Tindall D; Klein EA; Sharifi N
    Lancet Oncol; 2016 Oct; 17(10):1435-1444. PubMed ID: 27575027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
    Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
    JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
    Hearn JWD; Sweeney CJ; Almassi N; Reichard CA; Reddy CA; Li H; Hobbs B; Jarrard DF; Chen YH; Dreicer R; Garcia JA; Carducci MA; DiPaola RS; Sharifi N
    JAMA Oncol; 2020 Apr; 6(4):e196496. PubMed ID: 32053149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
    Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
    JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.
    Han FF; Ren LL; Xuan LL; Lv YL; Liu H; Gong LL; An ZL; Liu LH
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):103-112. PubMed ID: 33141329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.
    Sharifi N; Diaz R; Lin HM; Roberts E; Horvath LG; Martin A; Stockler MR; Yip S; Subhash VV; Portman N; Davis ID; Sweeney CJ
    J Clin Invest; 2024 Sep; 134(18):. PubMed ID: 39286977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
    Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
    Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
    Hettel D; Sharifi N
    Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.
    Sharifi N; Azad AA; Patel M; Hearn JWD; Wozniak M; Zohren F; Sugg J; Haas GP; Stenzl A; Armstrong AJ
    Cell Rep Med; 2024 Aug; 5(8):101644. PubMed ID: 39168093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline HSD3B1 Genetics and Prostate Cancer Outcomes.
    Thomas L; Sharifi N
    Urology; 2020 Nov; 145():13-21. PubMed ID: 32866512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer.
    Stangl-Kremser J; Lemberger U; Hassler MR; Bruchbacher A; Ilijazi D; Garstka N; Kramer G; Haitel A; Abufaraj M; Shariat SF
    Clin Genitourin Cancer; 2019 Oct; 17(5):389-394. PubMed ID: 31331867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
    Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
    Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.
    Wu G; Huang S; Nastiuk KL; Li J; Gu J; Wu M; Zhang Q; Lin H; Wu D
    Prostate; 2015 May; 75(7):777-782. PubMed ID: 25731771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.
    Agarwal N; Hahn AW; Gill DM; Farnham JM; Poole AI; Cannon-Albright L
    JAMA Oncol; 2017 Jun; 3(6):856-857. PubMed ID: 28208175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
    Alyamani M; Emamekhoo H; Park S; Taylor J; Almassi N; Upadhyay S; Tyler A; Berk MP; Hu B; Hwang TH; Figg WD; Peer CJ; Chien C; Koshkin VS; Mendiratta P; Grivas P; Rini B; Garcia J; Auchus RJ; Sharifi N
    J Clin Invest; 2018 Aug; 128(8):3333-3340. PubMed ID: 29939161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
    Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
    JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes.
    McKay RR; Nelson TJ; Pagadala MS; Teerlink CC; Gao A; Bryant AK; Agiri FY; Guram K; Thompson RF; Pridgen KM; Seibert TM; Lee KM; Carter H; Lynch JA; Hauger RL; Rose BS
    JAMA Netw Open; 2024 Mar; 7(3):e242976. PubMed ID: 38506808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
    Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
    Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.